Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.QRxPharma has executed a license and option agreement (LOA) with Actavis to commercialize MoxDuo IR in the US acute pain marketplace.
Subscribe to our email newsletter
As per the agreement, Actavis has exclusive rights to commercialize and further develop MoxDuo IR for the US market.
Actavis will assume all costs for product launch as well as ongoing marketing and sales efforts in the US.
With the initiation of MoxDuo IR launch, QRxPharma is eligible to receive royalties of 10% to 30% depending on net sales thresholds, except for a period starting 3-6 months following launch where QRxPharma will receive a 50% royalty on $150m in cumulative sales.
The LOA also provides Actavis an option to negotiate for US marketing and sales rights of MoxDuo CR as well as MoxDuo IV.
Actavis US chief executive officer Doug Boothe said the launch plans for MoxDuo IR are on track and the company remain convinced MoxDuo IR is very well suited to the experience and expertise of its marketing and sales teams.